Vidipha Central Pharmaceutical JSC (HOSE:VDP)
55,900
0.00 (0.00%)
At close: May 19, 2026
HOSE:VDP Revenue
Vidipha Central Pharmaceutical JSC had revenue of 195.92B VND in the quarter ending March 31, 2026, a decrease of -6.84%. This brings the company's revenue in the last twelve months to 971.25B, up 4.29% year-over-year. In the year 2025, Vidipha Central Pharmaceutical JSC had annual revenue of 985.64B with 5.47% growth.
Revenue (ttm)
971.25B
Revenue Growth
+4.29%
P/S Ratio
1.27
Revenue / Employee
2.07B
Employees
469
Market Cap
1.23T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 985.64B | 51.15B | 5.47% |
| Jan 1, 2025 | 934.49B | -84.83B | -8.32% |
| Dec 31, 2023 | 1.02T | 11.52B | 1.14% |
| Jan 1, 2023 | 1.01T | 800.84B | 386.97% |
| Dec 31, 2008 | 206.95B | 15.51B | 8.10% |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DHG Pharmaceutical JSC | 5.27T |
| Traphaco JSC | 2.74T |
| Imexpharm | 2.39T |
| Domesco Medical Import - Export Joint-Stock | 2.12T |
| Cuu Long Pharmaceutical JSC | 1.31T |
| OPC Pharmaceutical JSC | 1.13T |
| Ben Tre Pharmaceutical JSC | 860.31B |
| Mediplantex National Pharmaceutical JSC | 366.83B |